Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GNBT Generex -- Ignore unavailable to you. Want to Upgrade?

To: MJ who wrote (286)	9/24/2010 12:50:15 PM
From: MJ	Read Replies (1) \| Respond to of 310

This is what I am understanding from Investor Relations. Company does not want to do a reverse split however it is a requirement to stay listed on the NASDAQ. The question I ask after conversation with IR----this is a Canadian Company so why is the Nasdaq the most important place for GNBT to be------------certainly a Canadian exchange could be utilized as well. There was no comment on Pfizer or Merck and their relationship or non-relationship to any future plans when asked about Pfizer and Merck. My personal recommendation to IR was that if they want to stay on the Nasdaq then do the reverse split with rights or warrants attached to the new shares to be exercised at a future date by holders at the time of the reverse split or as of the record date for voting. Rights and warrants are an old-fashioned mode of raising money for a company and benefitting shareholders in the future. It works. I was promised that my recommendation would be forwarded to the board--------obviously only as an opinion. mj